S-1/A: Profusa Secures $100M Equity Facility, Shifts to Bitcoin Treasury

Profusa, Inc. filed an S-1 registration statement for the resale of up to 8.97 million common shares by Ascent Partners Fund LLC, tied to a $100 million committed equity facility primarily for Bitcoin purchases.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corporation) filed an S-1 registration statement for the resale of up to 8,970,830 shares of common stock by Ascent Partners Fund LLC.
• The shares are linked to a Common Stock Purchase Agreement dated July 28, 2025, allowing Profusa to sell up to $100,000,000 in aggregate gross proceeds to Ascent over 36 months.
• Proceeds from sales to Ascent will primarily be used to purchase Bitcoin, provided the company's cash balance exceeds $5,000,000; otherwise, proceeds will first bring the balance to $5,000,000, then purchase Bitcoin.
• The shares offered for resale include 8,070,830 Purchase Shares and 900,000 Commitment Warrant Shares, issuable upon exercise of warrants with an exercise price of $0.01.
• The number of Commitment Warrant Shares will be reduced to 450,000 if Profusa does not require Ascent to purchase any Purchase Shares within 100 days of the Purchase Agreement execution.
• Profusa will not receive any proceeds from Ascent's resale of these shares, but may receive up to $100,000,000 from direct sales to Ascent under the Purchase Agreement.
• The purchase price per share for sales to Ascent will be 97% of the lowest volume-weighted average price (VWAP) during a 10-day valuation period, subject to a floor price.
• Profusa recently completed a business combination (reverse recapitalization) with NorthView Acquisition Corporation on July 11, 2025, becoming the successor SEC registrant.
• Profusa is a clinical-stage digital health and medical technology company developing biointegrated sensors, including the Lumee Oxygen Platform (CE Mark approved in EU) and Lumee Glucose Platform (in clinical trials).
• The company has incurred significant net operating losses since inception, with a working capital deficit of $63.2 million as of June 30, 2025, and a net loss of $5.1 million for the six months ended June 30, 2025.
• Management believes current liquidity is not sufficient to alleviate substantial doubt about the company's ability to continue as a going concern within one year from the issuance date of the financial statements (August 2026).
• Profusa's patent portfolio includes 20 issued U.S. patents and 80 rest-of-world patents, expiring between March 2030 and January 2040.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including substantial doubt about its going concern ability, recurring losses, and delisting from Nasdaq. While it has secured a potential equity facility, its reliance on Bitcoin for treasury management introduces significant volatility, and its core products are still in early commercialization or development stages with uncertain regulatory timelines.

Positives

• Secured a committed equity facility of up to $100,000,000 with Ascent Partners Fund LLC, providing a potential source of capital.
• Successfully completed a business combination on July 11, 2025, transitioning to a public company.
• Lumee Oxygen Platform has received CE Mark approval in the EU and is targeting commercialization in Europe in early 2026.
• Lumee Glucose Platform has shown promising proof-of-concept clinical data with a Mean Absolute Relative Difference (MARD) of approximately 11% and up to nine months of functionality post-injection, with zero device-related serious adverse events (SAE) in trials involving 54 subjects.
• Strong intellectual property portfolio with 20 issued U.S. patents and 80 rest-of-world patents, protecting its biosensor technology.
• Strategic plan to leverage data streams from its platform for high-growth healthcare sectors like telemedicine and health and wellness coaching.
• Management believes the Lumee Glucose solution could benefit a much larger patient population beyond current Type 1 diabetes, including Type 2 and pre-diabetes.

Negatives

• Substantial doubt about the ability to continue as a going concern, with recurring losses from operations and a working capital deficit of $63.2 million as of June 30, 2025.
• Net loss of $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Cash and cash equivalents were only $0.1 million as of June 30, 2025.
• Proceeds from the committed equity facility will be used primarily for Bitcoin purchases, introducing significant volatility and risk to the company's treasury strategy.
• The company will not receive any proceeds from the resale of shares by the Selling Stockholder, only from direct sales to Ascent.
• The actual number of shares sold under the Purchase Agreement and the gross proceeds are unpredictable due to market conditions and the fluctuating price of common stock.
• Significant dilution to existing stockholders is expected from the sale and issuance of common stock to the Selling Stockholder.
• Lumee Oxygen is not yet approved for commercial sale in the U.S., and Lumee Glucose is not authorized for commercial sale in any jurisdiction.
• The company is in default on a PPP Loan 2 ($1.3 million outstanding) and certain promissory notes ($0.9 million outstanding as of June 30, 2025).
• Material weaknesses identified in internal control over financial reporting, including segregation of duties and review of accounts payable/accrued liabilities.
• The company was delisted from Nasdaq on December 27, 2024, and its securities are now quoted on the OTC Market, which can negatively impact liquidity and market price.
• The company has an excise tax payable of $1,952,662 as of June 30, 2025, which was not paid by the due date and is accruing interest and penalties.

Risks

• It is not possible to predict the actual number of shares of Common Stock, if any, that will be sold under the Purchase Agreement to Ascent, or the actual gross proceeds resulting from those sales.
• The sale and issuance of Common Stock to the Selling Stockholder will cause dilution to existing stockholders, and the sale of ELOC Shares acquired by the Selling Stockholder, or the perception that such sales may occur, could cause the price of Common Stock to fall.
• Investors who buy ELOC Shares from the Selling Stockholder at different times will likely pay different prices.
• The net proceeds from sales of shares of Common Stock made pursuant to the Purchase Agreement will primarily be used to purchase Bitcoin, the price of which has been, and will likely continue to be, highly volatile.
• Substantial doubt exists about the ability to continue as a going concern, which may hinder the ability to obtain further financing.
• The company has a limited operating history and has incurred losses since inception, anticipating continued significant losses for at least the next several years.
• Operating in a highly competitive market with large, well-established companies with significant resources may prevent effective competition.
• International operations expose the company to risks such as local product preferences, longer payment cycles, foreign currency fluctuations, less intellectual property protection, trade protection measures, and compliance with foreign regulatory requirements and anti-bribery laws.
• Consumer confusion about product features and technology could lead to purchasing competitive products or conflating adverse events with Profusa's products.
• The commercialization of the Lumee Oxygen Platform is expected to generate nearly all commercial revenue until regulatory approval for additional products is obtained.
• Dependence on third-party suppliers and outsourcing makes the company vulnerable to supply disruptions, suboptimal quality, noncompliance, and price fluctuations.
• There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of products, and failure to obtain necessary clearances or approvals would adversely affect business growth.
• Inability to successfully complete pre-clinical studies or clinical trials necessary to support additional PMA, De Novo, or 510(k) applications or supplements could impair commercialization of CGM systems.
• Products may cause or contribute to adverse medical events or be subject to failures or malfunctions that are required to be reported to the FDA, potentially leading to sanctions or recalls.
• Quality problems could lead to recalls or safety alerts, reputational harm, and material adverse effects on business.
• Changes to the regulatory landscape may impact the ability to obtain marketing authorization for future product developments.
• Failure to comply with laws, regulations, and contract requirements relating to reimbursement of health care goods and services may subject the company to penalties.
• Subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and security, which could result in claims, penalties, and increased operational costs.
• Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems, leading to harm to customers, expenses, liability, and reputational damage.
• May become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit product shipments, require licenses, or result in monetary damages.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Inability to protect intellectual property rights throughout the world could materially and negatively affect the business.
• Failure to protect the confidentiality of trade secrets could materially adversely affect the value of technology and harm the business.
• May need or choose to obtain licenses from third parties to advance research or commercialize products, and there is no assurance such licenses would be obtainable.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and non-compliance could reduce or eliminate patent protection.
• Patent terms may be inadequate to protect the competitive position on products for an adequate amount of time.
• Failure to obtain patent term extension and/or data exclusivity for any product candidates developed as drug product candidates may materially harm the business.
• May be subject to claims challenging the inventorship or ownership of patents and other intellectual property.
• Intellectual property rights do not necessarily address all potential threats.
• Inability to successfully maintain effective internal control over financial reporting could adversely impact investor confidence and stock price.
• Environmental, social, and corporate governance (ESG) regulations, policies, and provisions may make the supply chain more complex and adversely affect customer relationships.
• Current uncertainty in domestic and global economic and political conditions makes it difficult to predict product demand and could cause actual results to differ materially from expectations.
• Changes in financial accounting standards or practices or existing taxation rules may cause adverse unexpected revenue and/or expense fluctuations.
• Identified material weaknesses in internal control over financial reporting could continue to adversely affect the ability to report accurately and timely.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
• The Bitcoin treasury strategy exposes the company to various risks associated with Bitcoin, including high volatility, lack of interest/dividends, untested strategy, counterparty risks (custodians), and regulatory uncertainty.
• Regulatory change reclassifying Bitcoin as a security could lead to classification as an investment company under the Investment Company Act of 1940, adversely affecting Bitcoin's market price and the company's common stock.
• Exposure to risk of non-performance by counterparties in the Bitcoin treasury strategy.
• Security breaches or cyberattacks, or loss/destruction of private keys, could result in loss of some or all Bitcoin holdings.
• A temporary or permanent blockchain fork to Bitcoin or other crypto assets could adversely affect the business.
• Due diligence procedures to mitigate transaction risk may fail to prevent transactions with sanctioned entities.
• No assurance of compliance with Nasdaq continued listing standards, potentially resulting in delisting.
• Future sales, or the perception of future sales, by shareholders in the public market could cause the market price for common stock to decline.
• The grant and future exercise of registration rights may adversely affect the market price of shares.
• Shares reserved for future issuance under the Equity Incentive Plan will become eligible for sale, causing dilution.
• No current plans to pay cash dividends on common stock for the foreseeable future.
• Issuance of additional shares of common stock or other equity securities without stockholder approval would dilute ownership interests and may depress the market price.
• Anti-takeover provisions in the amended and restated certificate of incorporation and under Delaware law could make an acquisition more difficult.
• Exclusive forum provisions could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• May be subject to securities litigation, which is expensive and could divert management attention.

Future Outlook

Profusa expects to continue incurring significant losses for several years as it builds commercial infrastructure, develops new products, and conducts clinical trials. The company aims to commercialize the Lumee Oxygen Platform in Europe in early 2026 and in the U.S. in late 2026, subject to FDA approval. The Lumee Glucose Platform is targeted for a European launch in 2025 and U.S. FDA approval in late 2026 or early 2027. Proceeds from the committed equity facility will primarily fund Bitcoin purchases, provided cash balances exceed $5 million. Profusa plans to expand its product portfolio to include sensors for other analytes and partner with telemedicine and health and wellness coaching sectors to leverage its data streams.

Management Comments

• Management believes this liquidity [from PIPE Convertible Note] has not alleviated the relevant conditions or events that raise substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.
• Management believes that its technological approach may create advantages to current glucose monitoring solutions on the market to substantially increase the number of users who can benefit from this data stream from the current type 1 diabetes population to the much larger type 2 and pre-diabetes populations.
• Profusa believes that the combination of the potential advantages of this platform will enable it to generate both short-term revenue in the high-value clinical applications of wound care and diabetes management as noted above, but to also leverage core technology and develop and add to Profusa's product portfolio to potentially tackle the management of other chronic conditions, while in the future creating the foundation for the technology enabled health care where the large volume of biomarker data aligned with up-to-the-minute actions and choices of the individual.
• Profusa believes that, at scale, the data Profusa's platform generates from its initial products will be a key enabler for the productivity and business models for both of these sectors to expand and reach more of their full potential.

Industry Context

The medical device market, particularly for glucose monitoring, is highly competitive and characterized by rapid technological advancements. Profusa faces competition from established players like Abbott, Medtronic, and Roche in CGM, and Siemens Healthineers in oxygen monitoring. The broader healthcare industry is trending towards technology-enabled solutions, with significant growth in telemedicine (over $80 billion in 2021) and remote coaching platforms (nearly $14 billion). Government initiatives like CMS reimbursement codes for remote patient monitoring (over $200 monthly per patient) provide momentum for Profusa's platform. However, the global economy is experiencing high inflation and tightening financial conditions, which could negatively impact product demand and access to capital.

Comparison to Industry Standards

• Lumee Glucose's potential for a Mean Absolute Relative Difference (MARD) of approximately 11% and up to nine months of functionality post-injection aims to surpass the typical 7-14 day sensor life of current short-term needle-type Continuous Glucose Monitors (CGMs) from competitors like Dexcom and Abbott.
• The ease of deployment for Lumee Glucose, requiring a simple hypodermic needle injection versus surgical implantation for some long-term solutions (e.g., Senseonics Eversense E3), offers a less invasive alternative designed to encourage broader patient and physician adoption.
• Profusa's platform is positioned to offer a more cost-effective and user-friendly solution compared to existing CGM devices, which often have high costs that limit insurance reimbursement to only the most severe Type 1 and Type 2 diabetes patients.

Management Changes

Corporate Governance

Legal Proceedings

• Currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million.
• No other currently pending legal proceedings are believed to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• Investor Rights Agreement, Voting Agreement, and Co-Sale Agreement with certain preferred and common stockholders (including affiliates of directors and executive officers) terminated upon the closing of the merger.
• APAC Joint Venture Term Sheet with Carbis Bay Limited, BC hSensor Limited, and Tasly (International) Healthcare Capital Company Limited for commercialization in the Asia Pacific region, with Tasly Holding Group Co. Ltd. or its affiliates expected to purchase 60% of the JV for $6 million.
• Tasly Convertible Debt: A short-term loan agreement with Tasly (International) Healthcare Investment & Development Company Limited (a shareholder) for up to $1.6 million, bearing 12% interest (24% default rate), which matured on December 31, 2023, and was extended to March 31, 2024. The company is currently in default on this loan.
• Equity Grants: Stock options have been granted to executive officers and certain directors.
• Severance Arrangements: Dr. Hwang's offer letter provides six months base salary plus a pro-rata bonus and COBRA premiums upon termination without cause.
• NorthView Related Party Transactions (Pre-Business Combination): Included founder shares purchased by the Sponsor, private placement warrants purchased by the Sponsor and underwriters, an administrative services agreement with NorthView Sponsor I, LLC (terminated June 30, 2023), a Convertible Working Capital Promissory Note with the Sponsor ($1,919,796 outstanding as of June 30, 2025, convertible into common stock at $2.22 per share, repayment deferred), advances from Profusa to NorthView ($1,299,040 owed as of June 30, 2025), and $50,000 due to a related party for administrative service fees.

Stakeholder Impact

• Shareholders face significant dilution from the potential issuance and sale of common stock under the committed equity facility and the resale of shares by the Selling Stockholder.
• Investors are exposed to high volatility and risk due to the company's treasury strategy of primarily purchasing Bitcoin.
• Employees and management face uncertainty due to the company's 'going concern' doubt and the need for additional financing.
• Customers may be impacted by potential delays in product commercialization and regulatory approvals, as well as any adverse events or recalls.
• Creditors, particularly those holding defaulted loans, face repayment uncertainty, although the company expects to repay some upon the business combination closing.
• Regulatory bodies will continue to oversee the company's compliance with medical device regulations, financial reporting, and tax obligations, especially given identified material weaknesses and excise tax defaults.

Next Steps

• Obtain FDA clearance or approval for Lumee Oxygen Platform in the U.S.
• Commercialize Lumee Oxygen in Europe starting early 2026.
• Obtain regulatory approval for Lumee Glucose in Europe (expected 2025) and the U.S. (late 2026/early 2027).
• Conduct a next validation study for Lumee Glucose in the first half of 2026.
• Prepare IDE submission documentation for Lumee Glucose study conduct in the U.S.
• Seek additional financing through equity offerings or debt financings.
• Continue to build European and United States commercial infrastructure.
• Enhance existing products and develop new ones.
• Continue discussions with potential partners in Asia for the APAC Joint Venture.
• Strategically engage in commercial B2B relationships for coaching, telemedicine, and health and wellness segments.
• Remediate material weaknesses in internal control over financial reporting.
• Finalize accounting conclusions on Commitment Warrants and validate their debt classification for September 30, 2025 financial statements.
• Update disclosures and provide revised pro forma financial information if 900,000 warrants become probable and measurable.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial doubt about its ability to continue as a going concern, recurring significant losses, and a large working capital deficit. The delisting from Nasdaq to the OTC Market further reduces liquidity and investor confidence. While the committed equity facility offers a potential capital source, its primary use for Bitcoin purchases introduces extreme volatility and risk, which is highly speculative for a medical technology company. The company is also in default on existing loans and has identified material weaknesses in internal controls. Despite promising product development, the financial instability and high-risk treasury strategy make the stock a strong sell for a seasoned investor.

Keywords

Biointegrated sensors, Continuous Glucose Monitoring, CGM, Lumee Oxygen, Lumee Glucose, Medical Technology, Digital Health, SEC Filing, S-1, Equity Facility, Bitcoin Treasury, SPAC, Profusa Inc., NorthView Acquisition Corporation, Risk Factors, Corporate Governance, Intellectual Property, Clinical Trials, FDA Approval, CE Mark, Nasdaq Delisting, OTC Market, Dilution, Going Concern